<DOC>
	<DOCNO>NCT03096782</DOCNO>
	<brief_summary>The goal clinical research study learn give 1 unit expand cord blood combine 1 unit non-expanded cord blood patient leukemia lymphoma help transplant `` take '' faster . The safety combination also study . Chemotherapy and/or 1 dose radiation therapy also give transplant .</brief_summary>
	<brief_title>Cord Blood ( CB ) Ex-vivo Mesenchymal Stem Cell ( MSC ) Expansion + Fucosylation</brief_title>
	<detailed_description>Study Plans : If participant agrees take part study , back-up source cord blood choose participant . This blood reserve National Marrow Donor Program place hold case need quickly emergency . The blood place hold study doctor decide transplant successful . Once back-up cord blood collect , participant admit hospital follow participant 's assign schedule study treatment . Participant 's doctor choose one follow 3 study plan base disease , participant 's age , participant 's medical history . Plan 1 : Fludarabine/Clofarabine/Busulfan/Rituximab/Total Body Irradiation : If participant 1 55 year age receive high-dose chemotherapy , participant 55 65 year old participant 's doctor agree , participant receive fludarabine , clofarabine , busulfan , antithymocyte globulin ( ATG ) , total body irradiation , possibly rituximab . Please note Day 0 day cord blood transplant , negative day number use label treatment day transplant . Participant receive test dose busulfan vein 60 minute outpatient . If test dose give outpatient , participant admit hospital Day -11 ( 11 day participant 's transplant ) receive fluid vein receive busulfan test dose Day -10 . This low-level `` test '' dose busulfan check level busulfan participant 's blood change time . This information use decide next dose need reach target blood level match participant 's body size . About 11 sample blood draw pharmacokinetic ( PK ) test busulfan . PK test measure amount study drug body different time point . These blood sample draw various timepoints start busulfan infusion continue next 11 hour . The blood sample repeat first day high-dose busulfan treatment . Each sample 1 teaspoon blood . A temporary heparin lock place participant 's vein lower number needle stick need draws . If possible PK test perform technical scheduling reason , participant receive standard fix dose busulfan . If participant receive test dose outpatient , participant admit hospital Day -10 receive fluid vein . If participant 's doctor think appropriate disease , participant receive rituximab vein 4-6 hour Day -10 . If participant receive test dose inpatient , participant admit hospital Day -11 receive fluid vein . If appropriate disease , participant receive rituximab vein 4-6 hour Day -11 . Participant receive ATG vein 4 hour Days -9 -8 . ATG design weaken participant 's immune system order low risk participant 's body reject transplant . On Days -7 -4 , participant receive fludarabine vein 1 hour , clofarabine vein 1 hour , busulfan vein 3 hour . On Day -3 , participant receive single treatment low-dose total body irradiation . Participant rest ( receive chemotherapy drug ) Days -2 -1 . On Day 0 , participant receive participant 's cord blood transplant CVC . Plan 2 : Fludarabine/Melphalan : If participant 's doctor choose fludarabine melphalan , participant follow schedule : On Day -9 , participant admit hospital receive fluid vein . On Days -8 -7 , participant receive ATG vein 4 hour . On Day -6 , participant receive drug . On Days -5 , -4 , -3 , participant receive fludarabine vein 30 minute . On Day -2 , participant receive fludarabine vein 30 minute melphalan vein 30 minute . On Day -1 , participant receive drug . On Day 0 , participant receive participant 's cord blood transplant CVC . Plan 3 : Fludarabine/Cyclophosphamide/Total Body Irradiation : If participant 's doctor choose fludarabine , cyclophosphamide , total body irradiation , participant follow schedule : On Day -9 , participant admit hospital receive fluid vein . On Days -8 -7 , participant receive ATG vein 4 hour . On Day -6 , participant receive fludarabine vein 30 minute cyclophosphamide vein 1 hour . Participant also receive mesna vein 30 minute time , cyclophosphamide dose . Mesna give low risk side effect bladder cause cyclophosphamide . On Days -5 , -4 , -3 , participant receive fludarabine vein 30 minute . On Day -2 , participant receive drug . On Day -1 , participant receive single treatment low-dose total body irradiation . On Day 0 , participant receive participant 's cord blood transplant CVC . Supportive Drugs : Starting Day -3 , participant receive MMF tablet mouth 2 time day . If participant able take tablet mouth , participant receive MMF vein 2 hour 2 time day . If participant graft-versus-host disease ( GVHD ) Day 100 participant 's cord blood transplant , dose MMF gradually lower . GVHD transplant donor tissue attack tissue recipient 's body . If participant GVHD , MMF may stop 7 day GVHD control . Starting Day -2 , participant receive tacrolimus vein continuous ( nonstop ) infusion participant able take mouth . Participant take tacrolimus mouth 2 time day 6 month . After , participant 's tacrolimus dose may gradually lower participant GVHD . Participant 's doctor discus participant . Starting Day 0 , participant receive filgrastim ( G-CSF ) needle skin 1 time day every day participant 's white blood count begin recover . Nurses teach participant caregiver perform injection participant 's . Filgrastim design help cell bone marrow divide , help raise white blood cell count quickly , lower fever , decrease risk infection . Length Study : Participant study 1 year . Participant take study early disease get bad , intolerable side effect occur , cord blood infect transplant , participant unable follow study direction , participant 's doctor think participant 's best interest . Participation study last study visit . Study Visits : At 1 , 3 , 6 , 12 month transplant : - Participant physical exam . - Participant check possible reaction transplant study drug , include GVHD . - Blood ( 4 teaspoon ) draw routine test , check infection , genetic test learn donor 's cell `` take '' . Urine collect routine test . The routine blood test urine collection routine test repeat often doctor think need . - If doctor think need , participant bone marrow aspiration check status disease . To collect bone marrow aspirate , area hip site numb anesthetic , small amount bone marrow withdrawn large needle . Participant need stay hospital 4 week . After participant leaf hospital , participant continue outpatient hospital area , mean participant stay close enough able come back visit 100 day transplant . This investigational study . Adding sugar cord blood cell FDA-approved process . It currently use research purpose . Fludarabine , busulfan , clofarabine , melphalan , mycophenolate mofetil ( MMF ) , tacrolimus , rituximab FDA approve commercially available give patient leukemia lymphoma cord blood transplant . Total body irradiation deliver use FDA-approved commercially available method . The study doctor explain study treatment design work . Up 25 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>1 . Patients must one follow hematologic malignancy : . Acute Myelogenous Leukemia ( AML ) , induction failure , highrisk relapse first remission ( intermediaterisk highrisk cytogenetics , flt3 mutation positive and/or evidence minimal residual disease flow cytometry ) , secondary leukemia prior chemotherapy and/or arise MDS , Langerhan 's cell histiocytosis , disease beyond first remission . 2 . Myelodysplastic Syndrome ( MDS ) : Primary therapy relate . 3 . Acute Lymphoblastic Leukemia ( ALL ) : induction failure , primary refractory treatment ( achieve complete remission first course therapy ) beyond first remission include second great remission active disease . Patients first remission eligible consider high risk , define follow detected time : translocation 9 ; 22 4 ; 11 , hypodiploidy , complex karyotype , secondary leukemia develop cytotoxic drug exposure , and/or evidence minimal residual disease , acute biphenotypic leukemia , double hit nonHodgkin 's lymphoma . 4 . NonHodgkin 's Lymphoma ( NHL ) primary induction failure , second third complete remission , refractory disease , relapse ( include relapse post autologous hematopoietic stem cell transplant ) . Double hit lymphoma first remission advance disease . 5 . Small Lymphocytic Lymphoma ( SLL ) , Chronic Lymphocytic Leukemia ( CLL ) progressive disease follow standard therapy . 6 . CML second chronic phase accelerate phase . 7 . Hodgkin 's Disease ( HD ) : Induction failure , second third complete remission , relapse ( include relapse post autologous hematopoietic stem cell transplant ) . 8 . Patients Age Criteria : Age &gt; /= 1 &lt; /= 65 year old . Eligibility pediatric patient determine conjunction MDACC pediatrician . 9 . Performance score least 80 % Karnofsky PS &lt; 3 ( ECOG ) ( age &gt; /= 12 year ) , Lansky PlayPerformance Scale least 60 % great ( age &lt; 12 year ) . 10 . Adequate major organ system function demonstrate : . Left ventricular ejection fraction &gt; 40 % ; b . Pulmonary function test ( PFT ) demonstrate diffusion capacity least 50 % predict . For child &lt; /= 7 year age unable perform PFT , oxygen saturation &gt; /= 92 % room air pulse oximetry ; c. Creatinine &lt; 1.6 mg/dL ; d. SGPT/bilirubin &lt; /= 2.0 x normal . 11 . Negative Beta HCG test woman child bear potential define postmenopausal 12 month previous surgical sterilization willing use effective contraceptive measure study . 12 . Patients must two CB unit available match patient 4 , 5 , 6/6 HLA class I ( serological ) II ( molecular ) antigen . Each cord must contain least 1.5 x 10^7 total nucleated cells/Kg recipient body weight ( prethaw ) . 13 . Have identify back cell source case engraftment failure . The source autologous , related unrelated . 1 . Patients known history HIV/AIDS . 2 . Active CNS disease patient history CNS malignancy . 3 . Patients chronic active hepatitis cirrhosis . If positive hepatitis serology , Study Chair may deem patient eligible base result liver biopsy . 4 . Patients uncontrolled serious medical condition persistent septicemia despite adequate antibiotic therapy , decompensated congestive heart failure despite cardiac medication pulmonary insufficiency require intubation ( exclude primary disease CB transplantation propose ) , psychiatric condition would limit informed consent . 5 . Positive beta HCG female childbearing potential define postmenopausal 12 month previous surgical sterilization breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>NHL</keyword>
	<keyword>Small Lymphocytic Lymphoma</keyword>
	<keyword>SLL</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>Hodgkin 's Disease</keyword>
	<keyword>HD</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Myleran</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>ATG</keyword>
	<keyword>ATG ( rabbit )</keyword>
	<keyword>Rabbit Antithymocyte Globulin</keyword>
	<keyword>Rabbit Antilymphocyte Globulin</keyword>
	<keyword>Rabbit ATG</keyword>
	<keyword>rATg</keyword>
	<keyword>Thymoglobulin</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludarabine Phosphate</keyword>
	<keyword>Fludara</keyword>
	<keyword>Clofarabine</keyword>
	<keyword>Clofarex</keyword>
	<keyword>Clolar</keyword>
	<keyword>Total Body Irradiation</keyword>
	<keyword>TBI</keyword>
	<keyword>XRT</keyword>
	<keyword>External Beam Radiotherapy</keyword>
	<keyword>Mycophenolate Mofetil</keyword>
	<keyword>MMF</keyword>
	<keyword>CellCept</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Prograf</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Neupogen</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Alkeran</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>Mesna</keyword>
	<keyword>Mesnex</keyword>
	<keyword>Cord Blood Transplantation</keyword>
	<keyword>Stem Cell Transplant</keyword>
</DOC>